

GET BACK  
TO AN  
**ACTIVE LIFE**



**VISCALGIC**<sup>®</sup>  
ORAL VISCOSUPPLEMENTATION

## WHAT IS OSTEOARTHRITIS ?

Osteoarthritis (OA) is the most frequent joint disorder and one of the most common chronic diseases. Characterized by a cartilage erosion, OA gradually worsens over time and can become rapidly painful and incapacitating.


OA can develop in any joint in the body, but most commonly affects knees, hips, hands, neck and lower back.

The main symptoms are chronic pain, stiffness and loss of mobility.

## WHAT IS HYALURONIC ACID ?

Hyaluronic acid (HA) is a major component of the synovial fluid and cartilage, and is responsible for the lubrication and cushioning in joints.

It decreases friction between joint surfaces and protects soft tissue from trauma by acting as a shock absorbant. HA also have analgesic, anti-inflammatory, antioxidant and chondroprotective effects.



In OA joints, the quality and quantity of HA are diminished. As a result, the synovial fluid has lower viscosity and elasticity, decreasing its ability to lubricate the joint and absorb shocks. The articular surfaces are therefore altered and the cartilage degraded by the forces of friction and compression, leading to significant pain and function loss

## WHAT IS VISCOSUPPLEMENTATION ?

At present, restoring the viscoelasticity of the synovial fluid by intra-articular administration of HA, called viscosupplementation (VS), is the treatment of choice for OA patients. Compared with NSAIDs and corticosteroids, VS avoids the adverse events linked to these drugs, provides longer effects, treats not only pain but also stiffness and loss of motion, and protects cartilage.



In OA knee, the HA concentration of the synovial fluid is low. As a result, the cartilage is exposed to frictional and compressional damage.



The supplementation of HA in the synovial fluid improves lubrication and cushioning in the knee.

## WHAT IS ORAL VISCOSUPPLEMENTATION ?

According to the current protocol, HA should be administered repeatedly into the joint cavity (1 to 5 injections every 6 months). This necessity for multiple injections and sessions is a major drawback of the therapy. To be treated with HA, patients must visit clinics repeatedly and must undergo the discomfort and risk of complication associated with the repetition of injections. Considering these disadvantages, it is far more desirable to supplement the joint in HA by non-invasive delivery. VISCALGIC® follows this strategy and provides an oral viscosupplementation.

Contrary to theoretical predictions, clinical studies have shown that the symptoms of OA are alleviated by HA ingestion. Orally administered HA is absorbed without substantial degradation, distributed to synovial joints while preserving its biological activities, and is retained in the tissues for prolonged periods.



**VISCALGIC®**  
ORAL VISCOSUPPLEMENTATION

ENJOYING  
**COMFORTABLE  
MOVEMENTS**



MAKE  
**THE RIGHT MOVE**

## WHAT IS **VISCALGIC**® ?

VISCALGIC® is an orally administered product for viscosupplementation indicated to support joint comfort, cartilage health and articular mobility. VISCALGIC® delivers a substantial quantity of HA inside the joint tissues to relieve pain and stiffness and to improve mobility and articular function.

## HOW DOES IT **WORK** ?

The oral HA is absorbed and distributed to bone, cartilage and synovial fluid and is retained in those tissues for prolonged periods. As a result, the quantity and quality of HA are restored, thus ensuring a good lubrication and shock absorption in the joint.

## WHAT ARE **THE BENEFICIAL EFFECTS** ?

VISCALGIC® improves joint function, reduces stiffness and increases the range of motion.

- ▶ JOINT COMFORT
- ▶ CARTILAGE HEALTH
- ▶ ARTICULAR MOBILITY



## CLINICAL RESULTS




Fig. 1 Improvements in stiffness ( $P < 0.001$ ).




Fig. 2 Improvements in physical function ( $P < 0.001$ ).



PATIENT  
**SATISFACTION\***

\* Patient satisfaction at 3 months - Viscalgic - 92 patients - September 2021

  
**VISCALGIC**<sup>®</sup>  
ORAL VISCOSUPPLEMENTATION

CLINICALLY  
**PROVEN EFFICACY**




## SPECIFICATIONS

	 (hyaluronic acid) capsules	 (hyaluronic acid and glucosamine) capsules
COMPOSITION	HYALURONIC ACID	HYALURONIC ACID + GLUCOSAMINE
HA CONTENT	120 MG PER CAPSULE	120 MG PER 3 CAPSULES
GLUCOSAMINE CONTENT	NONE	1500 MG PER 3 CAPSULES
HA MOLECULAR WEIGHT	1 MILLION DALTON	
EFFECTS	JOINT COMFORT, MOBILITY IMPROVEMENT, CARTILAGE HEALTH	
ADMINISTRATION	ORAL	
DOSAGE	1 CAPSULE DAILY	3 CAPSULES DAILY
ONSET OF EFFECTS	A COUPLE OF WEEKS OF REGULAR INTAKE	
DURATION OF EFFECTS	UP TO 3 MONTHS AFTER THE LAST INTAKE	
PACKAGING	BOTTLE OF 120 CAPSULES	
STORAGE	AT ROOM TEMPERATURE IN A DRY ENVIRONMENT	

VISCALGIC® and VISCALGIC® GS are composed of pharmaceutical-grade ingredients of non-animal origin manufactured through a biofermentation process. As a result, VISCALGIC® and VISCALGIC® GS have a high purity, an improved biological activity and are free from animal proteins potentially responsible for allergenic reactions as well as from transmissible infectious agents (viruses and prions).

VISCALGIC® and VISCALGIC® GS are suitable for halal, kosher, vegan and vegetarian diets.

VISCALGIC® and VISCALGIC® GS are manufactured in the United Kingdom under strict quality control and in small batches in order to provide only fresh products.



  
**VISCALGIC®**  
 ORAL VISCOSUPPLEMENTATION

A SAFE AND  
**RELIABLE THERAPY**

For more information, visit  
[www.viscalgic.com](http://www.viscalgic.com)



manufactured by:  
ORGEV LABORATORIES LTD.  
Novatex Bioengineering division  
MK44 1LQ Sharnbrook  
United Kingdom  
[www.novatex-bioeng.com](http://www.novatex-bioeng.com)